Skip to Main content Skip to Navigation
Conference papers

Repeated imaging of lung cancer development using PIXSCAN, a low dose micro-CT scanner based on XPAD hybrid pixel detectors

Abstract : PIXSCAN is the first micro-CT prototype based on XPAD hybrid pixel detectors whose properties (high signal to noise ratio and high detection efficiency) allow imaging at low irradiation dose. We have tested the impact of repeated imaging sessions with PIXSCAN on living mice. Mice were subjected on average to 10 imaging sessions over two weeks without any detectable sign of X-ray injuries as assessed by spontaneous activity in the cage, examination of hair and skin, or comparison of lung absorbing properties for X-rays. PIXSCAN was therefore used to non-invasively monitor the progression of lung metastasis in a murine model of cancer. Aim of was two-fold: i) to provide imaging assistance to decide timing of animal sacrifice and subsequent histological characterization of the tumors; ii) to optimize imaging protocol to allow direct evaluation of new therapeutic agents to stop cancer progression. Comparing in vivo tomographic reconstruction of freely breathing mice with post mortem examination of their lungs, we have shown that identification and localization of millimetric tumors was compatible with our low dose X-ray imaging protocol, allowing determination of tumor growth kinetics. In this context, interest of respiratory gating will be discussed.
Complete list of metadatas

http://hal.in2p3.fr/in2p3-00322271
Contributor : Danielle Cristofol <>
Submitted on : Wednesday, September 17, 2008 - 10:46:26 AM
Last modification on : Wednesday, October 14, 2020 - 3:47:01 AM

Identifiers

Collections

Citation

F. Debarbieux, A. Bonissent, P. Breugnon, F. Cassol-Brunner, P. Delpierre, et al.. Repeated imaging of lung cancer development using PIXSCAN, a low dose micro-CT scanner based on XPAD hybrid pixel detectors. World Molecular Imaging Congress 2008, Sep 2008, Nice, France. pp.242 - 245, ⟨10.1109/TNS.2009.2037319⟩. ⟨in2p3-00322271⟩

Share

Metrics

Record views

176